Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779125 | 0.87 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2LMNAGPBAR1PDE10A | |
| SCHEMBL2567854 | 0.85 | LMNA (0.69) | CYSLTR1CYSLTR2LMNAGPBAR1PDE10A | |
| SCHEMBL7975209 | 0.80 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL26632677 | 0.79 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL26632681 | 0.78 | CYSLTR1 (0.75) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL26774780 | 0.78 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL26632675 | 0.76 | CYSLTR1 (0.78) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL26771291 | 0.75 | CYSLTR1 (0.75) | CYSLTR1CYSLTR2GPBAR1PDE10AFFAR1 | |
| SCHEMBL13772898 | 0.75 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2GPBAR1PDE10ASMN1; SMN2 | |
| SCHEMBL13772899 | 0.75 | PDE10A (0.73) | CYSLTR1CYSLTR2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6214842-B1 | TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA TYPICALLY ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE; TREATING DIABETES TYPES I AND II | WYETH | 2001-04-10 | — | — | US | disclosed |